Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns

Area of Science:

• Public Health
• Infectious Disease Prevention
• Pharmacovigilance

Background:

• Pre-exposure prophylaxis (PrEP) is a key strategy for reducing human immunodeficiency virus (HIV) incidence.
• Safety concerns can impede the widespread implementation and use of PrEP.
• Understanding PrEP's safety profile is crucial for its effective application.

Purpose of the Study:

• To review safety concerns associated with pre-exposure prophylaxis (PrEP) based on clinical trials.
• To evaluate the safety and efficacy of PrEP interventions.
• To inform guidelines for safe and effective PrEP use.

Main Methods:

• Literature search of PubMed, AVAC database, clinicaltrials.gov, and Google Scholar.
• Inclusion of 11 clinical trials reporting safety and efficacy data as of April 2016.
• Review of real-world practice reports alongside clinical trial findings.

Main Results:

• PrEP, using tenofovir disoproxil fumarate/emtricitabine (Truvada®) or tenofovir, demonstrates efficacy in reducing HIV incidence.
• The primary adverse effects are mild to moderate gastrointestinal issues (nausea, vomiting, diarrhea).
• Monitoring of liver enzymes, renal function, and bone mineral density is advised.

Conclusions:

• PrEP exhibits a favorable benefit-risk profile for HIV prevention in clinical trials.
• Widespread PrEP use is recommended, contingent on adherence monitoring and post-marketing safety surveillance.
• Real-world data is essential to confirm the sustained benefits observed in clinical settings.